)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Arcutis Biotherapeutics
Arcutis Biotherapeutics (ARQT) investor relations material
Arcutis Biotherapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary6 May, 2026
Executive summary
Net product revenues reached $105.4 million in Q1 2026, up 65% year-over-year, driven by strong ZORYVE demand, expanded indications, and improved payer contracting, despite seasonality and severe weather impacts.
ZORYVE continued to gain market share, holding 48% of branded nonsteroidal topical prescriptions and outperforming the overall topical market and branded non-steroidals.
Net loss narrowed to $11.3 million from $25.1 million year-over-year, reflecting higher sales and improved operating leverage.
Strategic investments in sales force expansion, direct-to-consumer campaigns, and pipeline development are positioning for growth inflection in 2027 and beyond.
Advanced pipeline with new clinical trials and regulatory submissions, including sNDA for ZORYVE cream 0.05% in infants and initiation of Phase 1 trial for ARQ-234.
Financial highlights
Product revenue, net, rose 65% year-over-year to $105.4 million, with ZORYVE foam and cream 0.15% showing triple-digit growth.
Cost of sales increased to $9.8 million from $8.8 million in Q1 2025, reflecting higher sales volume.
R&D expenses rose to $30.6 million, mainly due to a $10 million milestone for ARQ-234 trial initiation.
SG&A expenses increased 16% year-over-year to $74.1 million, reflecting commercialization investments.
Net loss per share improved to $(0.09) from $(0.20) year-over-year.
Outlook and guidance
Revenue guidance for full-year 2026 maintained at $480–$495 million.
Expectation of robust quarter-over-quarter net sales growth for the remainder of 2026, driven by demand and gross-to-net improvements.
Anticipate operating leverage and cash flow generation to increase meaningfully in 2027 as investment needs moderate.
Results from ongoing Phase 2 studies for ZORYVE foam in vitiligo and hidradenitis suppurativa expected in Q4 2026 and Q1 2027.
Existing capital resources of $224.3 million are projected to fund operations for at least 12 months from the reporting date.
Primary care and pediatrics sales team strategy
Impact of Q1 seasonality on full-year guidance
Clinical timeline and positioning for ARQ-234
Explain the CD200R strategy given OX40 failures
Sales force mix for the infant AD segment
ZORYVE's role as adjunctive therapy in HS
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arcutis Biotherapeutics
- Board recommends director elections, auditor ratification, and pay approval, with strong governance and ESG focus.ARQT
Proxy filing22 Apr 2026 - Key votes include director elections, auditor ratification, and executive compensation approval.ARQTProxy filing22 Apr 2026
- Raising 2026 revenue guidance, ZORYVE accelerates growth with new indications and expanded access.ARQT25th Annual Needham Virtual Healthcare Conference14 Apr 2026
- 2025 revenue up 123% to $372.1M, Q4 net income $17.4M, 2026 guidance raised to $480–495M.ARQTQ4 20259 Apr 2026
- ZORYVE's rapid growth and expanding indications drive strong financial and market performance.ARQTCorporate presentation1 Apr 2026
- Strong revenue growth, sales force expansion, and pipeline advances position for multi-billion potential.ARQTTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Expanding indications and evolving guidelines drive strong growth and new opportunities for ZORYVE.ARQTGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Strong product launches and broad access strategies fuel growth and financial stability.ARQTGoldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026
- FDA approved ZORYVE cream 0.15% for atopic dermatitis, expanding access via Kowa partnership.ARQTFDA Announcement2 Feb 2026
Next Arcutis Biotherapeutics earnings date
Q2 20265 Aug, 2026
Arcutis Biotherapeutics
Next Arcutis Biotherapeutics earnings date
Q2 20265 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage